NEW YORK, Feb. 5 - MDS Proteomics has acquired roughly 2,000 disease-related, full-length cDNA clones from Japan's Kazusa DNA Research Institute, MDS said on Tuesday.

The three-year deal "is a major step" to help MDS meet its goal of discovering 1,000 new drug targets in the next five years, according to Frank Gleeson, president and CEO of MDS Proteomics.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.